Showing 5291-5300 of 9561 results for "".
- The American Skin Association Re-ups Support for the SPOTS Programhttps://practicaldermatology.com/news/the-american-skin-association-re-ups-support-for-the-spots-program/2461023/The American Skin Association (ASA) is renewing its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a public health outreach educational program aimed at both elementary school students and young teenagers. The comprehensive pr
- Lilly's Lebrikizumab Plus Topical Corticosteroids Offer Improvement and Itch Relief in Atopic Dermatitishttps://practicaldermatology.com/news/lillys-lebrikizumab-plus-topical-corticosteroids-offer-improvement-and-itch-relief-in-atopic-dermatitis/2461015/Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's third pivotal Phase 3 trial (ADhere). By Week 16, the study met all primary and k
- Otezla Becomes First Oral Psoriasis Treatment Approved Across All Disease Severitieshttps://practicaldermatology.com/news/otezla-becomes-first-oral-psoriasis-treatment-approved-across-all-disease-severities/2461014/Otezla® (apremilast) from Amgen is now approved for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. This expanded indication makes Otezla the first and only oral treatment approved 
- Rinvoq Scores FDA Nod for Active Psoriatic Arthritishttps://practicaldermatology.com/news/rinvoq-scores-us-fda-nod-for-active-psoriatic-arthritis/2461012/The U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. "The efficacy
- NKTR-358 Demonstrates Proof of Concept in ADhttps://practicaldermatology.com/news/nktr-358-demonstrates-proof-of-concept-in-ad/2461011/Nektar Therapeutics and its partner Eli Lilly & Company’s NKTR-358 (LY3471851), a novel T regulatory (Treg) cell stimulator, demonstrated proof of concept in a Phase 1b study of patients with moderate-to-severe atopic dermatitis. The findings were presented at Eli Lilly&n
- BTL Launches Scholarship Program with Professional Basketball Player Andre Drummondhttps://practicaldermatology.com/news/btl-launches-scholarship-program-with-professional-basketball-player-andre-drummond/2460991/The BTL SCHOLAR DRAFT will grant five student athletes $15,000 each toward their college tuition. In addition, BTL has partnered with renowned, professional basketball player Andre Drummond to promote the BTL SCHOLAR DRAFT and award the winners. The program officially ki
- Gryphon Investors to Acquire Revision Skincarehttps://practicaldermatology.com/news/gryphon-investors-to-acquire-revision-skincare/2460984/Gryphon Investors is set to acquire Revision Skincare and Goodier Cosmetics. The middle-market private equity firm has signed a definitive agreement to acquire the skincare company, with an anticipating closing date this year. Financial terms of the transaction were not disclosed.
- Almirall US Supports The Skin Cancer Foundation’s Mobile Skin Cancer Screening Programhttps://practicaldermatology.com/news/almirall-us-supports-the-skin-cancer-foundations-mobile-skin-cancer-screening-program/2460983/Almirall US is supporting The Skin Cancer Foundation’s mobile skin cancer screening program, Destination Healthy Skin. The Destination Healthy Skin RV travels to cities across the US, where local volunteer dermatologists provide free full-body skin cancer screenings in private exam rooms ab
- University of Arkansas Researcher Scores $1.6M NIH Grant for Research on Chronic Skin Woundshttps://practicaldermatology.com/news/puniversity-of-arkansas-researcher-scores-16m-nih-grant-for-research-on-chronic-skin-wounds/2460976/University of Arkansas biomedical engineering professor Kyle Quinn received a four-year, $1.6 million grant from the National Institutes of Health to develop non-invasive, real-time “optical biopsies” of chronic skin wounds. The goal is to provide digital histopathology imag
- Resilia Pharmaceuticals Obtains Marketing License for Solace Eczema Creamhttps://practicaldermatology.com/news/resilia-pharmaceuticals-obtains-marketing-license-for-solace-eczema-cream/2460967/Resilia Pharmaceuticals, Inc. will market and sell Solace™ Eczema Cream, a medical device, as an OTC product in the US, after signing a license agreement with Pelle Ventures, LLC. Financial terms of the transaction were not disclosed. Previously only avai